Comment
doi: 10.1056/NEJMc2036175.
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
Affiliations
- PMID: 33730469
- DOI: 10.1056/NEJMc2036175
Item in Clipboard
Comment
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
N Engl J Med.
.
No abstract available
Comment in
-
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply.N Engl J Med. 2021 Mar 18;384(11):e42. doi: 10.1056/NEJMc2036175. N Engl J Med. 2021. PMID: 33730470 No abstract available.
Comment on
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Clinical Trial.
Similar articles
-
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.N Engl J Med. 2021 Mar 18;384(11):e42. doi: 10.1056/NEJMc2036175. N Engl J Med. 2021. PMID: 33730468 No abstract available.
-
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.N Engl J Med. 2021 Mar 18;384(11):e42. doi: 10.1056/NEJMc2036175. N Engl J Med. 2021. PMID: 33730467 No abstract available.
-
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.N Engl J Med. 2021 Mar 18;384(11):e42. doi: 10.1056/NEJMc2036175. N Engl J Med. 2021. PMID: 33730466 No abstract available.
-
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.Expert Rev Clin Pharmacol. 2022 May;15(5):501-513. doi: 10.1080/17512433.2022.2094770. Epub 2022 Jul 3. Expert Rev Clin Pharmacol. 2022. PMID: 35762406 Review.
-
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.Expert Opin Drug Saf. 2022 Sep;21(9):1161-1170. doi: 10.1080/14740338.2022.2130889. Epub 2022 Oct 6. Expert Opin Drug Saf. 2022. PMID: 36174659 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
